pentobarbital will minimize the extent or outcome of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Use of alternative treatment plans is strongly suggested when linagliptin will be to be administered using a CYP3A4 inducerpentobarbital will lessen the level or effect of buprenorphine subdermal implant by